Allogene Therapeutics, Inc. Overview
Pro stress-test →Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease. The company is developing "off-the-shelf" CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Strategic Profile
Pro stress-test →After nearly eight years of platform development and treatment of more than 200 patients across six clinical studies, Allogene has built an off-the-shelf CAR T platform designed to deliver clinical utility, broad patient access, predictable manufacturing, and scalable economics. The company has achieved a burn rate 28% lower than its 2023 peak with runway spanning two pivotal data-readout years, which buys ALLO time to execute without needing dilutive financing.
Competitive Landscape
Pro stress-test →Allogene has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. As a clinical-stage company, Allogene competes with autologous CAR-T leaders (Gilead/Kite, Novartis) and emerging allogeneic competitors, differentiated by its off-the-shelf manufacturing approach and potential for broader scalability.
Industry Context
Allogene Therapeutics, Inc. operates in Biopharmaceutical / Cell Therapy (Allogeneic CAR-T).
Key facts
Founded: 2017 · Headquarters: South San Francisco, California · Revenue: $22K · Market cap: $2.4B